0.8057
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: - GuruFocus
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq
Coherus BioSciences (NASDAQ:CHRS) Rating Lowered to Sell at StockNews.com - Defense World
COHERUS BIOSCIENCES Earnings Preview: Recent $CHRS Insider Trading, Hedge Fund Activity, and More - Nasdaq
Coherus BioSciences (CHRS) Q1 Earnings Preview: Declining Revenue Expected - GuruFocus
Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings - GuruFocus
Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus By Investing.com - Investing.com Australia
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):